TEM, or Tempus AI, Inc., is a healthcare technology company that uses artificial intelligence and multimodal clinical data to power precision medicine, offering genomic diagnostics and data-licensing services to clinicians and pharmaceutical partners. In today's session, TEM traded down approximately 8.99% to $76.04, compared with a previous close of $83.55. The move marked a sharp reversal of the prior day's rally, as markets digested heavy insider selling and took profits following a recent run-up.
The decline came on the heels of a powerful prior-session advance, when TEM jumped about 9% after the company received FDA 510(k) clearance for Tempus ECG-MR, an AI tool that flags possible mitral regurgitation from standard ECG readings, and after Guggenheim raised its price target on the stock. Such outsized single-day gains frequently invite profit-taking the following session, and today's reversal returned the shares to roughly the level where they traded before the clearance-driven pop. The giveback suggests that near-term traders locked in gains rather than any deterioration in the company's fundamentals.
Investor attention also turned to ongoing insider transactions. Founder, chairman, and CEO Eric Lefkofsky has sold more than 1 million Class A shares across multiple trades since mid-September, at prices between roughly $76 and $81. While routine executive selling can be part of pre-planned diversification, the scale and timing of the disposals — coming as the stock sat near its recent highs — were cited by market participants as a negative signal that pressured TEM shares.
Adding to the selling pressure were signs of cautious positioning in the options market, where traders were reported to have sold far out-of-the-money calls while buying out-of-the-money puts in late August, reflecting limited conviction in further upside. The stock, which carries a notably high beta and has been a favorite among high-momentum AI investors, was also caught up in broader rotation away from speculative growth names in the session, amplifying its move relative to the broader market.
The pullback in TEM was more pronounced than the broader tape, underscoring the stock-specific and momentum-driven nature of the decline. Trading volume was elevated as the session progressed, consistent with active repositioning following the prior day's breakout. The reversal brought the shares back toward a zone that several sell-side analysts have flagged as near fair value — a number of recently initiated or updated ratings carry price objectives at or below the stock's pre-decline levels — reinforcing the notion that valuation itself became a source of resistance after the rapid climb.
Looking ahead, investors will watch whether TEM can hold key technical support and whether the pullback stabilizes or extends. The company's next quarterly earnings report is a key near-term catalyst, along with progress on reimbursement expansion for its diagnostics portfolio, the integration of its planned Personalis acquisition, and upcoming renewals of major data-licensing contracts. Risks include continued insider selling, the company's still-negative profitability, and the sensitivity of a high-multiple growth stock to shifting risk appetite in the AI sector.
For investors seeking a more systematic approach to navigating fast-moving names like TEM, Tickeron's Trending AI Robots page offers a curated look at the platform's strongest-performing AI trading bots. Tickeron hosts hundreds of bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Only the bots demonstrating the best results under current market conditions are featured in this section, helping traders quickly identify approaches that are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TEM advanced for three days, in 114 of 129 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 26 of 31 cases where TEM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TEM as a result. In 31 of 36 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
TEM moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
TEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for TEM moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 19 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 10-day moving average for TEM crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for TEM entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (31.261) is slightly higher than the industry average of (4.353). TEM has a moderately low P/E Ratio (-53.201) as compared to the industry average of (13.253). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry